Manufacturer of Controlled Substances; Notice of Application, 45784 [E8-17962]
Download as PDF
<![CDATA[
45784
Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–18065 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 28, 2008,
Chattem Chemicals Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by
renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
mstockstill on PROD1PC66 with NOTICES
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 3, 2008,
Chemic Laboratories, Inc., 480 Neponset
Street, Building 7, Canton,
Massachusetts 02021, made application
by renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of Cocaine (9041), a basic
class of controlled substance listed in
schedule II.
The company plans to manufacture
small quantities of the above listed
controlled substance for distribution to
its customers for the purpose of
research.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 6, 2008.
Dated: July 28, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17955 Filed 8–5–08; 8:45 am]
4-Methoxyamphetamine (7411) ....
Difenoxin (9168) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) .............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Meperidine (9230) .........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Noroxymorphone (9668) ...............
Alfentanil (9737) ............................
Sufentanil (9740) ..........................
Fentanyl (9801) .............................
16:46 Aug 05, 2008
Jkt 214001
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 6, 2008.
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17961 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
VerDate Aug<31>2005
I
I
II
II
II
II
II
II
II
II
II
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 3, 2008,
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) as a bulk manufacturer of
Morphine (9300), a basic class of
controlled substance listed in schedule
II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 6, 2008.
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–17962 Filed 8–5–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 28, 2008,
Boehringer Ingelheim Chemicals, Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Amphetamine (1100) ....................
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Methadone (9250) ........................
E:\FR\FM\06AUN1.SGM
06AUN1
Schedule
II
II
II
II
]]>Agencies
[Federal Register Volume 73, Number 152 (Wednesday, August 6, 2008)]
[Notices]
[Page 45784]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-17962]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on July 3, 2008, Cambridge
Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made
application by renewal to the Drug Enforcement Administration (DEA) as
a bulk manufacturer of Morphine (9300), a basic class of controlled
substance listed in schedule II.
The company plans to utilize small quantities of the listed
controlled substance in the preparation of analytical standards.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substance, may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than October 6, 2008.
Dated: July 29, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-17962 Filed 8-5-08; 8:45 am]
BILLING CODE 4410-09-P
